Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Deferred Revenue (2016 - 2025)

AC Immune (ACIU) has disclosed Current Deferred Revenue for 10 consecutive years, with $104.7 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 7.87% to $104.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $104.7 million through Dec 2025, up 7.87% year-over-year, with the annual reading at $104.7 million for FY2025, 7.87% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $104.7 million at AC Immune, up from $97.1 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $104.7 million in Q4 2025, with the low at $155574.9 in Q4 2023.
  • Average Current Deferred Revenue over 5 years is $40.7 million, with a median of $777588.0 recorded in 2021.
  • The sharpest move saw Current Deferred Revenue crashed 74.47% in 2023, then soared 62309.34% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $777588.0 in 2021, then decreased by 21.64% to $609318.9 in 2022, then plummeted by 74.47% to $155574.9 in 2023, then skyrocketed by 62309.34% to $97.1 million in 2024, then grew by 7.87% to $104.7 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $104.7 million, $97.1 million, and $155574.9 for Q4 2025, Q4 2024, and Q4 2023 respectively.